Clinical Trial Update: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating Revumenib in relapsed/refractory leukemias including MLL/KMT2A rearrangements or NPM1 mutations; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Leukemia of Ambiguous Lineage
• Mixed Lineage Acute Leukemia
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: RECRUITING